Eli Lilly's David Ricks snared $24M pay package in a year turbo-boosted by Covid-19 antibody

Boosted by booming sales of its Covid-19 antibody bamlanivimab, Eli Lilly posted double-digit growth in 2020 despite a more steady showing from its legacy portfolio. In his fourth year at the helm, CEO David Ricks will tout 2020 as a win — particularly for his pocketbook.